{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:40:28Z","timestamp":1775666428000,"version":"3.50.1"},"reference-count":221,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>After the influenza pandemic (1918), COVID-19 was declared a Vth pandemic by the WHO in 2020.\nSARS-CoV-2 is an RNA-enveloped single-stranded virus. Based on the structure and life cycle, Protease\n(3CLpro), RdRp, ACE2, IL-6, and TMPRSS2 are the major targets for drug development against COVID-19.\nPre-existing several drugs (FDA-approved) are used to inhibit the above targets in different diseases. In coronavirus\ntreatment, these drugs are also in different clinical trial stages. Remdesivir (RdRp inhibitor) is the only\nFDA-approved medicine for coronavirus treatment. In the present study, by using the drug repurposing strategy,\n70 preexisting clinical or under clinical trial molecules were used in scrutiny for RdRp inhibitor potent molecules\nin coronavirus treatment being surveyed via docking studies. Molecular simulation studies further confirmed\nthe binding mechanism and stability of the most potent compounds. Docking studies were performed\nusing the Maestro 12.9 module of Schrodinger software over 70 molecules with RdRp as the target and\nremdesivir as the standard drug and further confirmed by simulation studies. The docking studies showed that\nmany HIV protease inhibitors demonstrated remarkable binding interactions with the target RdRp. Protease inhibitors\nsuch as lopinavir and ritonavir are effective. Along with these, AT-527, ledipasvir, bicalutamide, and\ncobicistat showed improved docking scores. RMSD and RMSF were further analyzed for potent ledipasvir and\nritonavir by simulation studies and were identified as potential candidates for corona disease. The drug repurposing\napproach provides a new avenue in COVID-19 treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The docking studies showed that many HIV protease inhibitors demonstrated remarkable binding interactions with the target rdrp. Protease inhibitors such as lopinavir and ritonavir are effective. Along with these, AT-527, ledipasvir, bicalutamide, and cobicistat showed improved docking scores. RMSD and RMSF were further analyzed for potent ledipasvir and ritonavir by simulation studies and were identified as potential candidates for corona disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612829666221107123841","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T05:12:46Z","timestamp":1667884366000},"page":"3677-3705","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial\nas RdRp Inhibitors in COVID-19 Treatment"],"prefix":"10.2174","volume":"28","author":[{"given":"Amita","family":"Verma","sequence":"first","affiliation":[{"name":"Bioorganic and Medicinal Chemistry Research Laboratory, Department of\nPharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irine","family":"Pauly","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Kumar Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adarsh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Thareja","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A.","family":"Kamal","sequence":"additional","affiliation":[{"name":"King Fahd\nMedical Research Center, King Abdulaziz University, Jaddah, Saudi Arabia"},{"name":"Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770,\nAustralia"},{"name":"Novel Global Community Educational Foundation, Australia Institutes for Systems Genetics, Frontiers Science Center\nfor Disease-related Molecular Network, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.chest.2020.09.077","volume":"159","author":"Patel M.","year":"2021","unstructured":"Patel M.; Dominguez E.; Sacher D.; Group TUC-R. Etoposide as salvage therapy for cytokine storm due to coronavirus disease 2019. Chest 2021,159(1),e7-e11","journal-title":"Chest"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bj.2020.04.007","volume":"43","author":"Liu Y.C.","year":"2020","unstructured":"Liu Y.C.; Kuo R.L.; Shih S.R.; COVID-19: The first documented coronavirus pandemic in history. Biomed J 2020,43(4),328-333","journal-title":"Biomed J"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.sintl.2020.100037","volume":"1","author":"Agarwal K.M.","year":"2020","unstructured":"Agarwal K.M.; Mohapatra S.; Sharma P.; Sharma S.; Bhatia D.; Mishra A.; Study and overview of the novel corona virus disease (COVID-19). Sens Int 2020,1,100037","journal-title":"Sens Int"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"114184","DOI":"10.1016\/j.bcp.2020.114184","volume":"180","author":"Chakraborty R.","year":"2020","unstructured":"Chakraborty R.; Parvez S.; COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol 2020,180,114184","journal-title":"Biochem Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1101\/2020.02.07.937862","author":"Gorbalenya A.","year":"2020","unstructured":"Gorbalenya A.; Baker S.; Baric R.; de Groot R.; Drosten C.; Gulyaeva A.; Severe acute respiratory syndrome-related coronavirus: The species and its viruses-A statement of the Coronavirus study group. bioRxiv 2020,7","journal-title":"bioRxiv"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1038\/nm1143","volume":"10","author":"Peiris J.S.M.","year":"2004","unstructured":"Peiris J.S.M.; Guan Y.; Yuen K.Y.; Severe acute respiratory syndrome. Nat Med 2004,10(S12)(Suppl.),S88-S97","journal-title":"Nat Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3201\/eid2602.190697","volume":"26","author":"Killerby M.E.","year":"2020","unstructured":"Killerby M.E.; Biggs H.M.; Midgley C.M.; Gerber S.I.; Watson J.T.; Middle East respiratory syndrome coronavirus transmission. Emerg Infect Dis 2020,26(2),191-198","journal-title":"Emerg Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P.","year":"2020","unstructured":"Zhou P.; Yang X.L.; Wang X.G.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-273","journal-title":"Nature"},{"key":"ref=9","author":"Tyrrell D.A.","year":"1996","unstructured":"Tyrrell D.A.; Myint S.H.; Coronaviruses. Medical Microbiology 1996","journal-title":"Medical Microbiology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1021\/acsinfecdis.0c00224","volume":"6","author":"Osman E.E.A.","year":"2020","unstructured":"Osman E.E.A.; Toogood P.L.; Neamati N.; COVID-19: Living through another pandemic. ACS Infect Dis 2020,6(7),1548-1552","journal-title":"ACS Infect Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31531\/2581-3080.1000153","volume":"4","author":"Jahangir M.A.","year":"2020","unstructured":"Jahangir M.A.; Muheem A.; Rizvi M.F.; Coronavirus (COVID-19): history, current knowledge and pipeline medications. Int J Pharm Pharmacol 2020,4(1),1-9","journal-title":"Int J Pharm Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.cca.2020.05.044","volume":"508","author":"Lotfi M.","year":"2020","unstructured":"Lotfi M.; Hamblin M.R.; Rezaei N.; COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020,508,254-266","journal-title":"Clin Chim Acta"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3390\/v13091782","volume":"13","author":"Gupta N.","year":"2021","unstructured":"Gupta N.; Kaur H.; Yadav P.D.; Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India. Viruses 2021,13(9),1782","journal-title":"Viruses"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/S2213-2600(21)00312-X","volume":"9","author":"Asrani P.","year":"2021","unstructured":"Asrani P.; Eapen M.S.; Hassan M.I.; Sohal S.S.; Implications of the second wave of COVID-19 in India. Lancet Respir Med 2021,9(9),e93-e94","journal-title":"Lancet Respir Med"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.27.21268278","author":"Lyngse F.P.","year":"2021","unstructured":"Lyngse F.P.; Mortensen L.H.; Denwood M.J.; SARS-CoV-2 Omicron VOC transmission in Danish households. medRxiv 2021","journal-title":"medRxiv"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","volume":"16","author":"Schoeman D.","year":"2019","unstructured":"Schoeman D.; Fielding B.C.; Coronavirus envelope protein: Current knowledge. Virol J 2019,16(1),69","journal-title":"Virol J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","volume":"14","author":"Astuti I.","year":"2020","unstructured":"Astuti I.; Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020,14(4),407-412","journal-title":"Diabetes Metab Syndr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.arcmed.2020.05.007","volume":"51","author":"Manhas S.","year":"2020","unstructured":"Manhas S.; Anjali A.; Mansoor S.; COVID-19 pandemic and current medical interventions. Arch Med Res 2020,51(6),473-481","journal-title":"Arch Med Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"173451","DOI":"10.1016\/j.ejphar.2020.173451","volume":"886","author":"Lam S.","year":"2020","unstructured":"Lam S.; Lombardi A.; Ouanounou A.; COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol 2020,886,173451","journal-title":"Eur J Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"173375","DOI":"10.1016\/j.ejphar.2020.173375","volume":"883","author":"Samudrala P.K.","year":"2020","unstructured":"Samudrala P.K.; Kumar P.; Choudhary K.; Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol 2020,883,173375","journal-title":"Eur J Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","volume":"28","author":"Trougakos I.P.","year":"2021","unstructured":"Trougakos I.P.; Stamatelopoulos K.; Terpos E.; Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci 2021,28(1),9","journal-title":"J Biomed Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.fmre.2021.01.013","volume":"1","author":"Su H.","year":"2021","unstructured":"Su H.; Xu Y.; Jiang H.; Drug discovery and development targeting the life cycle of SARS-CoV-2. Fund Res 2021,1(2),151-165","journal-title":"Fund Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1208\/s12249-020-01756-3","volume":"21","author":"Jamshaid H.","year":"2020","unstructured":"Jamshaid H.; Zahid F.; Din I.; Diagnostic and treatment strategies for COVID-19. AAPS PharmSciTech 2020,21(6),222","journal-title":"AAPS PharmSciTech"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"Taylor P.C.","year":"2021","unstructured":"Taylor P.C.; Adams A.C.; Hufford M.M.; de la Torre I.; Winthrop K.; Gottlieb R.L.; Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 2021,21(6),382-393","journal-title":"Nat Rev Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.4103\/jfmpc.jfmpc_728_20","volume":"9","author":"Sahu K.","year":"2020","unstructured":"Sahu K.; Kumar R.; Preventive and treatment strategies of COVID-19: From community to clinical trials. J Family Med Prim Care 2020,9(5),2149-2157","journal-title":"J Family Med Prim Care"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1076029620944497","author":"Haimei M.A.","year":"2020","unstructured":"Haimei M.A.; Pathogenesis and treatment strategies of COVID-19-related hypercoagulant and thrombotic complications. Clin Appl Thromb Hemost 2020,26","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13287-021-02334-5","volume":"12","author":"Singh B.","year":"2021","unstructured":"Singh B.; Mal G.; Verma V.; Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era. Stem Cell Res Ther 2021,12(1),283","journal-title":"Stem Cell Res Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"Singh T.U.","year":"2020","unstructured":"Singh T.U.; Parida S.; Lingaraju M.C.; Kesavan M.; Kumar D.; Singh R.K.; Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020,72(6),1479-1508","journal-title":"Pharmacol Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10238-020-00671-y","volume":"21","author":"Gavriatopoulou M.","year":"2021","unstructured":"Gavriatopoulou M.; Ntanasis-Stathopoulos I.; Korompoki E.; Emerging treatment strategies for COVID-19 infection. Clin Exp Med 2021,21(2),167-179","journal-title":"Clin Exp Med"},{"key":"ref=30","author":"Dorward J.","year":"2020","unstructured":"Dorward J.; Gbinigie K.;  Lopinavir\/ritonavir: A rapid review of effectiveness in COVID-19 Evidence Service to support the COVID-19 Centre for Evidence-Based Medicine 2020","journal-title":"Lopinavir\/ritonavir: A rapid review of effectiveness in COVID-19 Evidence Service to support the COVID-19 Centre for Evidence-Based Medicine"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jiph.2021.03.015","volume":"14","author":"Patel T.K.","year":"2021","unstructured":"Patel T.K.; Patel P.B.; Barvaliya M.; Saurabh M.K.; Bhalla H.L.; Khosla P.P.; Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health 2021,14(6),740-748","journal-title":"J Infect Public Health"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.3390\/ijms22115762","volume":"22","author":"Sojka D.","year":"2021","unstructured":"Sojka D.; \u0160nebergerov&#xE1; P.; Robbertse L.; Protease inhibition-An established strategy to combat infectious diseases. Int J Mol Sci 2021,22(11),5762","journal-title":"Int J Mol Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2020.06.032","volume":"156","author":"Sies H.","year":"2020","unstructured":"Sies H.; Parnham M.J.; Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. Free Radic Biol Med 2020,156,107-112","journal-title":"Free Radic Biol Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","volume":"150","author":"Lin M.H.","year":"2018","unstructured":"Lin M.H.; Moses D.C.; Hsieh C.H.; Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res 2018,150,155-163","journal-title":"Antiviral Res"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.14.250258","author":"Chen Y.","year":"2020","unstructured":"Chen Y.; Yang W.H.; Huang L.M.; Inhibition of severe acute respiratory syndrome coronavirus 2 main protease by tafenoquine in vitro. Biorxiv 2020","journal-title":"Biorxiv"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cbi.2019.02.017","volume":"303","author":"Jayachandran M.","year":"2019","unstructured":"Jayachandran M.; Wu Z.; Ganesan K.; Khalid S.; Chung S.M.; Xu B.; Isoquercetin upregulates antioxidant genes, suppresses inflammatory cytokines and regulates AMPK pathway in streptozotocin-induced diabetic rats. Chem Biol Interact 2019,303,62-69","journal-title":"Chem Biol Interact"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"659577","DOI":"10.3389\/fphar.2021.659577","volume":"12","author":"Alam S.","year":"2021","unstructured":"Alam S.; Kamal T.B.; Sarker M.M.R.; Zhou J.R.; Rahman S.M.A.; Mohamed I.N.; Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021. Front Pharmacol 2021,12,659577","journal-title":"Front Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.37201\/req\/002.2022","volume":"35","author":"Reina J.","year":"2022","unstructured":"Reina J.; Iglesias C.; Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination. Rev Esp Quimioter 2022,35(3),236-240","journal-title":"Rev Esp Quimioter"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7341493","volume":"2022","author":"Marzi M.","year":"2022","unstructured":"Marzi M.; Vakil M.K.; Bahmanyar M.; Zarenezhad E.; Paxlovid: Mechanism of action, synthesis, and in silico study. BioMed Res Int 2022,2022,1-16","journal-title":"BioMed Res Int"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","volume":"12","author":"Kokic G.","year":"2021","unstructured":"Kokic G.; Hillen H.S.; Tegunov D.; Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun 2021,12(1),279","journal-title":"Nat Commun"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","volume":"76","author":"Agrawal U.","year":"2020","unstructured":"Agrawal U.; Raju R.; Udwadia Z.F.; Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020,76(4),370-376","journal-title":"Med J Armed Forces India"},{"key":"ref=42","first-page":"e2020102","volume":"91","author":"Khalili H.","year":"2020","unstructured":"Khalili H.; Nourian A.; Ahmadinejad Z.; Efficacy and safety of sofosbuvir\/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed 2020,91(4),e2020102","journal-title":"Acta Biomed"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jmv.25798","volume":"92","author":"Khalili J.S.","year":"2020","unstructured":"Khalili J.S.; Zhu H.; Mak N.S.A.; Yan Y.; Zhu Y.; Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID\u201019. J Med Virol 2020,92(7),740-746","journal-title":"J Med Virol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"105180","DOI":"10.1016\/j.antiviral.2021.105180","volume":"195","author":"Julander J.G.","year":"2021","unstructured":"Julander J.G.; Demarest J.F.; Taylor R.; An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. Antiviral Res 2021,195,105180","journal-title":"Antiviral Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","volume":"6","author":"Cox R.M.","year":"2021","unstructured":"Cox R.M.; Wolf J.D.; Plemper R.K.; Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 2021,6(1),11-18","journal-title":"Nat Microbiol"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.07.028589","author":"Bukreyeva N.","year":"2020","unstructured":"Bukreyeva N.; Mantlo E.K.; Sattler R.A.; Huang C.; Paessler S.; Zeldis J.; The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. BioRxiv 2020","journal-title":"BioRxiv"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.09.21267566","author":"Song J.Y.","year":"2021","unstructured":"Song J.Y.; Kim Y.S.; Eom J.S.; Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity. medRxiv 2021","journal-title":"medRxiv"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","volume":"6","author":"Zhang J.L.","year":"2021","unstructured":"Zhang J.L.; Li Y.H.; Wang L.L.; Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther 2021,6(1),414","journal-title":"Signal Transduct Target Ther"},{"key":"ref=49","first-page":"13","author":"Zhao L.","year":"2022","unstructured":"Zhao L.; Li S.; Zhong W.; Mechanism of action of small-molecule agents in ongoing clinical trials for SARS-CoV-2: A review. In: Front Pharmaco 2022,13","journal-title":"In: Front Pharmaco"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-022-00895-6","volume":"16","author":"Qian H.","year":"2022","unstructured":"Qian H.; Wang Y.; Zhang M.; Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin 2022,16,1-9","journal-title":"Acta Pharmacol Sin"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/22221751.2022.2078230","volume":"11","author":"Shen Y.","year":"2022","unstructured":"Shen Y.; Ai J.; Lin N.; An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerg Microbes Infect 2022,11(1),1518-1523","journal-title":"Emerg Microbes Infect"},{"key":"ref=52","author":"Cadegiani FA","year":"2020","unstructured":"Cadegiani FA; McCoy J; Wambier CG; Proxalutamide (GT0918) reduces the rate of hospitalization and death in COVID-19 male patients: A randomized double-blinded placebo-controlled trial. 2020"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1021\/acsinfecdis.1c00278","volume":"7","author":"Carter-Timofte M.E.","year":"2021","unstructured":"Carter-Timofte M.E.; Arulanandam R.; Kurmasheva N.; Antiviral potential of the antimicrobial drug atovaquone against SARS-CoV-2 and emerging variants of concern. ACS Infect Dis 2021,7(11),3034-3051","journal-title":"ACS Infect Dis"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.12.246389","author":"Risner K.H.","year":"2020","unstructured":"Risner K.H.; Tieu K.V.; Wang Y.; Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture. BioRxiv 2020","journal-title":"BioRxiv"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","volume":"10","author":"Geriak M.","year":"2021","unstructured":"Geriak M.; Haddad F.; Kullar R.; Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia. Infect Dis Ther 2021,10(3),1323-1330","journal-title":"Infect Dis Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e13573","DOI":"10.1111\/dth.13573","volume":"33","author":"Hamouda Elgarhy L.","year":"2020","unstructured":"Hamouda Elgarhy L.; Could patients taking isotretinoin therapy be immune against SARS\u2010CoV\u20102? Dermatol Ther 2020,33(4),e13573","journal-title":"Dermatol Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e13943","DOI":"10.1111\/ijcp.13943","volume":"75","author":"Hosseinzadeh M.H.","year":"2021","unstructured":"Hosseinzadeh M.H.; Shamshirian A.; Ebrahimzadeh M.A.; Dexamethasone vs COVID\u201019: An experimental study in line with the preliminary findings of a large trial. Int J Clin Pract 2021,75(6),e13943","journal-title":"Int J Clin Pract"},{"key":"ref=58","doi-asserted-by":"publisher","DOI":"10.22541\/au.159493018.89024677","author":"Ferrara F.","year":"2020","unstructured":"Ferrara F.; Vitiello A.; The clinical rationale of Sacubitril\/valsartan for therapeutic treatment in SARS-CoV-2. Authorea Preprints 2020","journal-title":"Authorea Preprints"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00508-021-01855-6","volume":"133","author":"Vitiello A.","year":"2021","unstructured":"Vitiello A.; Ferrara F.; Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr 2021,133(17-18),983-988","journal-title":"Wien Klin Wochenschr"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"645194","DOI":"10.3389\/fendo.2021.645194","volume":"12","author":"Zangiabadian M.","year":"2021","unstructured":"Zangiabadian M.; Nejadghaderi S.A.; Zahmatkesh M.M.; Hajikhani B.; Mirsaeidi M.; Nasiri M.J.; The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: A systematic review. Front Endocrinol 2021,12,645194","journal-title":"Front Endocrinol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"105998","DOI":"10.1016\/j.ijantimicag.2020.105998","volume":"56","author":"Vankadari N.","year":"2020","unstructured":"Vankadari N.; Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents 2020,56(2),105998","journal-title":"Int J Antimicrob Agents"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e13492","DOI":"10.7759\/cureus.13492","volume":"13","author":"Cadegiani F.A.","year":"2021","unstructured":"Cadegiani F.A.; McCoy J.; Gustavo Wambier C.; Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: Results from a randomized, double-blinded, placebo-controlled trial. Cureus 2021,13(2),e13492","journal-title":"Cureus"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/14728222.2021.1944101","volume":"25","author":"Richardson E.","year":"2021","unstructured":"Richardson E.; Garc&#xED;a-Bernal D.; Calabretta E.; Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opin Ther Targets 2021,25(6),423-433","journal-title":"Expert Opin Ther Targets"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41467-021-21171-x","volume":"12","author":"Li F.","year":"2021","unstructured":"Li F.; Han M.; Dai P.; Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun 2021,12(1),866","journal-title":"Nat Commun"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.schres.2020.07.015","volume":"223","author":"Nobile B.","year":"2020","unstructured":"Nobile B.; Durand M.; Courtet P.; Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2? Schizophr Res 2020,223,373-375","journal-title":"Schizophr Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ijid.2020.10.093","volume":"102","author":"Takahashi W.","year":"2021","unstructured":"Takahashi W.; Yoneda T.; Koba H.; Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. Int J Infect Dis 2021,102,529-531","journal-title":"Int J Infect Dis"},{"key":"ref=67","volume":"9","author":"Goodman A.","year":"2021","unstructured":"Goodman A.; Repurposing drugs for the treatment of COVID-19. The Lancet Respiratory Medicine Available from:  (21)00270-8\/fulltext2021,9(7)","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11739-020-02383-3","volume":"15","author":"Depfenhart M.","year":"2020","unstructured":"Depfenhart M.; de Villiers D.; Lemperle G.; Meyer M.; Di Somma S.; Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? Intern Emerg Med 2020,15(5),801-812","journal-title":"Intern Emerg Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/bcpt.13533","volume":"128","author":"Breining P.","year":"2021","unstructured":"Breining P.; Fr&#xF8;lund A.L.; H&#xF8;jen J.F.; Camostat mesylate against SARS\u2010CoV\u20102 and COVID\u201019-Rationale, dosing and safety. Basic Clin Pharmacol Toxicol 2021,128(2),204-212","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/ph14010071","volume":"14","author":"Kotfis K","year":"2021","unstructured":"Kotfis K; Lechowicz K; Dro&#x17C;d&#x17C;al S; COVID-19-The potential beneficial therapeutic effects of spironolactone during SARS-CoV-2 infection. Pharmaceuticals 2021,14(1),71","journal-title":"Pharmaceuticals"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00228-020-02942-9","volume":"76","author":"Abobaker A.","year":"2020","unstructured":"Abobaker A.; Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome? Eur J Clin Pharmacol 2020,76(11),1619-1620","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=72","first-page":"249","volume":"4","author":"Leal C.M.R.","year":"2022","unstructured":"Leal C.M.R.; del Sol M.G.; Granado M.P.C.; Campos M.&#xC1;.; Prospective, non-controlled pilot study to evaluate the efficacy and safety of Cefditoren Pivoxil in COVID-19 patients with mild to moderate pneumonia. Eur J Res Med 2022,4(1),249-257","journal-title":"Eur J Res Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1007\/s11033-021-06770-7","volume":"48","author":"Al-kuraishy H.M.","year":"2021","unstructured":"Al-kuraishy H.M.; Al-Gareeb A.I.; Alzahrani K.J.; Alexiou A.; Batiha G.E.S.; Niclosamide for COVID-19: bridging the gap. Mol Biol Rep 2021,48(12),8195-8202","journal-title":"Mol Biol Rep"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12879-021-05983-2","volume":"21","author":"Roostaei Firozabad A.","year":"2021","unstructured":"Roostaei Firozabad A.; Meybodi Z.A.; Mousavinasab S.R.; Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial. BMC Infect Dis 2021,21(1),297","journal-title":"BMC Infect Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.1002\/slct.202101898","volume":"6","author":"Jovanovi\u0107 J\u0110","year":"2021","unstructured":"Jovanovi\u0107 J\u0110; Antonijevi\u0107 M; El-Emam AA; Markovi\u0107 Z; Comparative MD; Comparative MD study of inhibitory activity of opaganib and adamantane\u2010isothiourea derivatives toward COVID\u201019 main protease Mpro. ChemistrySelect 2021,6(33),8603-8610","journal-title":"ChemistrySelect"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13721-021-00341-3","volume":"11","author":"Alizadehmohajer N.","year":"2022","unstructured":"Alizadehmohajer N.; Behmardi A.; Najafgholian S.; Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking. Netw Model Anal Health Inform Bioinform 2022,11(1),11","journal-title":"Netw Model Anal Health Inform Bioinform"},{"key":"ref=77","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa127","volume":"161","author":"Mauvais-Jarvis F.","year":"2020","unstructured":"Mauvais-Jarvis F.; Klein S.L.; Levin E.R.; Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology 2020,161(9)","journal-title":"Endocrinology"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"e13733","DOI":"10.1111\/dth.13733","volume":"33","author":"Seirafianpour F.","year":"2020","unstructured":"Seirafianpour F.; Mozafarpoor S.; Fattahi N.; Sadeghzadeh-Bazargan A.; Hanifiha M.; Goodarzi A.; Treatment of COVID \u201019 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatol Ther 2020,33(4),e13733","journal-title":"Dermatol Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Belkaid Y.","year":"2014","unstructured":"Belkaid Y.; Hand T.W.; Role of the microbiota in immunity and inflammation. Cell 2014,157(1),121-141","journal-title":"Cell"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.3390\/ijerph17207618","volume":"17","author":"Al Bander Z.","year":"2020","unstructured":"Al Bander Z.; Nitert M.D.; Mousa A.; Naderpoor N.; The gut microbiota and inflammation: an overview. Int J Environ Res Public Health 2020,17(20),7618","journal-title":"Int J Environ Res Public Health"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3389\/fmicb.2020.01065","volume":"11","author":"Wang J.","year":"2020","unstructured":"Wang J.; Chen W.D.; Wang Y.D.; The relationship between gut microbiota and inflammatory diseases: The role of macrophages. Front Microbiol 2020,11,1065","journal-title":"Front Microbiol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2020.06.008","volume":"54","author":"Saleh J.","year":"2020","unstructured":"Saleh J.; Peyssonnaux C.; Singh K.K.; Edeas M.; Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion 2020,54,1-7","journal-title":"Mitochondrion"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.apsb.2020.09.013","volume":"11","author":"Zhang X.","year":"2021","unstructured":"Zhang X.; Han Y.; Huang W.; Jin M.; Gao Z.; The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B 2021,11(7),1789-1812","journal-title":"Acta Pharm Sin B"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1590\/S1516-635X2012000400005","volume":"14","author":"Oladele O.A.","year":"2012","unstructured":"Oladele O.A.; Emikpe B.O.; Adeyefa C.A.O.; Enibe F.; Effects of levamisole hydrochloride on cellular immune response and flock performance of commercial broilers. Rev Bras Cienc Avic 2012,14(4),259-265","journal-title":"Rev Bras Cienc Avic"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41598-021-04511-1","volume":"12","author":"Guardado-Mendoza R.","year":"2022","unstructured":"Guardado-Mendoza R.; Garcia-Maga&#xF1;a M.A.; Mart&#xED;nez-Navarro L.J.; Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. Sci Rep 2022,12(1),536","journal-title":"Sci Rep"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.seizure.2020.06.008","volume":"80","author":"G&#xF3;mez-Enjuto S.","year":"2020","unstructured":"G&#xF3;mez-Enjuto S.; Hernando-Requejo V.; Lape&#xF1;a-Motilva J.; Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-CoV-2 infected patient. Seizure 2020,80,157-158","journal-title":"Seizure"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1097\/CM9.0000000000001479","volume":"134","author":"Peng C.","year":"2021","unstructured":"Peng C.; Wang H.; Guo Y.F.; Calcium channel blockers improve prognosis of patients with coronavirus disease 2019 and hypertension. Chin Med J 2021,134(13),1602-1609","journal-title":"Chin Med J"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"577678","DOI":"10.3389\/fphar.2020.577678","volume":"11","author":"Stip E.","year":"2020","unstructured":"Stip E.; Rizvi T.A.; Mustafa F.; The large action of chlorpromazine: translational and transdisciplinary considerations in the face of COVID-19. Front Pharmacol 2020,11,577678","journal-title":"Front Pharmacol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","volume":"19","author":"Echeverr&#xED;a-Esnal D.","year":"2021","unstructured":"Echeverr&#xED;a-Esnal D.; Martin-Ontiyuelo C.; Navarrete-Rouco M.E.; Azithromycin in the treatment of COVID-19: A review. Expert Rev Anti Infect Ther 2021,19(2),147-163","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14787210.2021.1865803","volume":"19","author":"Narendrakumar L.","year":"2021","unstructured":"Narendrakumar L.; Joseph I.; Thomas S.; Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment. Expert Rev Anti Infect Ther 2021,19(8),1001-1008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jcph.1788","volume":"61","author":"Alavian G.","year":"2021","unstructured":"Alavian G.; Kolahdouzan K.; Mortezazadeh M.; Torabi Z.S.; Antiretrovirals for prophylaxis against COVID\u201019: A comprehensive literature review. J Clin Pharmacol 2021,61(5),581-590","journal-title":"J Clin Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.dsx.2020.09.027","volume":"14","author":"Pandey S.","year":"2020","unstructured":"Pandey S.; Pathak S.K.; Pandey A.; Ivermectin in COVID-19: What do we know? Diabetes Metab Syndr 2020,14(6),1921-1922","journal-title":"Diabetes Metab Syndr"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","volume":"5","author":"Roschewski M.","year":"2020","unstructured":"Roschewski M.; Lionakis M.S.; Sharman J.P.; Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020,5(48),eabd0110","journal-title":"Sci Immunol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"7074","DOI":"10.1200\/jco.2015.33.15_suppl.7074","volume":"33","author":"Patel M.R.","year":"2015","unstructured":"Patel M.R.; O\u2019Brien S.M.; Faia K.; Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-&#x3B4;,&#x3B3; inhibitor, in patients with treatment-na&#xEF;ve CLL. J Clin Oncol 2015,33(15)(_suppl.),7074","journal-title":"J Clin Oncol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1473-3099(20)30262-0","volume":"20","author":"Favalli E.G.","year":"2020","unstructured":"Favalli E.G.; Biggioggero M.; Maioli G.; Caporali R.; Baricitinib for COVID-19: A suitable treatment? Lancet Infect Dis 2020,20(9),1012-1013","journal-title":"Lancet Infect Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"e000741","DOI":"10.1136\/fmch-2020-000741","volume":"9","author":"Sayed Ahmed H.A.","year":"2021","unstructured":"Sayed Ahmed H.A.; Merrell E.; Ismail M.; Rationales and uncertainties for aspirin use in COVID-19: A narrative review. Fam Med Community Health 2021,9(2),e000741","journal-title":"Fam Med Community Health"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dkaa190","volume":"75","author":"Baldelli S.","year":"2020","unstructured":"Baldelli S.; Corbellino M.; Clementi E.; Cattaneo D.; Gervasoni C.; Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother 2020,75(9),2704-2706","journal-title":"J Antimicrob Chemother"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1177\/2472555220958385","volume":"25","author":"Maciorowski D.","year":"2020","unstructured":"Maciorowski D.; El Idrissi S.Z.; Gupta Y.; A review of the preclinical and clinical efficacy of remdesivir, hydroxychloroquine, and lopinavir-ritonavir treatments against COVID-19. SLAS Discov 2020,25(10),1108-1122","journal-title":"SLAS Discov"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"ofaa241","DOI":"10.1093\/ofid\/ofaa241","volume":"7","author":"Chen J.","year":"2020","unstructured":"Chen J.; Xia L.; Liu L.; Antiviral activity and safety of darunavir\/cobicistat for the treatment of COVID-19. Open Forum Infect Dis 2020,7(7),ofaa241","journal-title":"Open Forum Infect Dis"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","volume":"15","author":"Ghosh A.K.","year":"2007","unstructured":"Ghosh A.K.; Dawson Z.L.; Mitsuya H.; Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem 2007,15(24),7576-7580","journal-title":"Bioorg Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.1080\/07391102.2020.1791958","volume":"39","author":"Ibrahim M.A.A.","year":"2021","unstructured":"Ibrahim M.A.A.; Abdelrahman A.H.M.; Hegazy M.E.F.; In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn 2021,39(15),5756-5767","journal-title":"J Biomol Struct Dyn"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1038\/s41598-021-83229-6","volume":"11","author":"Weglarz-Tomczak E.","year":"2021","unstructured":"Weglarz-Tomczak E.; Tomczak J.M.; Talma M.; Burda-Grabowska M.; Giurg M.; Brul S.; Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci Rep 2021,11(1),3640","journal-title":"Sci Rep"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ddr.21895","volume":"83","author":"Hu S.","year":"2022","unstructured":"Hu S.; Jiang S.; Qi X.; Bai R.; Ye X.Y.; Xie T.; Races of small molecule clinical trials for the treatment of COVID\u201019: An up\u2010to\u2010date comprehensive review. Drug Dev Res 2022,83(1),16-54","journal-title":"Drug Dev Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1021\/acsptsci.1c00022","volume":"4","author":"Chen T.","year":"2021","unstructured":"Chen T.; Fei C.Y.; Chen Y.P.; Synergistic inhibition of SARS-CoV-2 replication using disulfiram\/ebselen and remdesivir. ACS Pharmacol Transl Sci 2021,4(2),898-907","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/s12885-018-4617-x","volume":"18","author":"Butcher K.","year":"2018","unstructured":"Butcher K.; Kannappan V.; Kilari R.S.; Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line. BMC Cancer 2018,18(1),753","journal-title":"BMC Cancer"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"101658","DOI":"10.1016\/j.jbc.2022.101658","volume":"298","author":"Chen Y.","year":"2022","unstructured":"Chen Y.; Yang W.H.; Chen H.F.; Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. J Biol Chem 2022,298(3),101658","journal-title":"J Biol Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12936-016-1145-5","volume":"15","author":"St Jean P.L.","year":"2016","unstructured":"St Jean P.L.; Xue Z.; Carter N.; Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J 2016,15(1),97","journal-title":"Malar J"},{"key":"ref=108","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12061302.v1","author":"Aly O.","year":"2020","unstructured":"Aly O.; Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease. ChemRxiv 2020","journal-title":"ChemRxiv"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/009127000204200902","volume":"42","author":"White C.M.","year":"2002","unstructured":"White C.M.; A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002,42(9),963-970","journal-title":"J Clin Pharmacol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ptr.7309","volume":"36","author":"Di Petrillo A.","year":"2022","unstructured":"Di Petrillo A.; Orr&#xF9; G.; Fais A.; Fantini M.C.; Quercetin and its derivates as antiviral potentials: A comprehensive review. Phytother Res 2022,36(1),266-278","journal-title":"Phytother Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1021\/acs.jnatprod.6b00274","volume":"79","author":"Kato K.","year":"2016","unstructured":"Kato K.; Ninomiya M.; Tanaka K.; Koketsu M.; Effects of functional groups and sugar composition of quercetin derivatives on their radical scavenging properties. J Nat Prod 2016,79(7),1808-1814","journal-title":"J Nat Prod"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/jnci\/80.19.1526","volume":"80","author":"van Maanen J.M.S.","year":"1988","unstructured":"van Maanen J.M.S.; Ret&#xE8;l J.; de Vries J.; Pinedo H.M.; Mechanism of action of antitumor drug etoposide: A review. J Natl Cancer Inst 1988,80(19),1526-1533","journal-title":"J Natl Cancer Inst"},{"key":"ref=113","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.28.470226","author":"Ullrich S.","year":"2021","unstructured":"Ullrich S.; Ekanayake K.B.; Otting G.; Nitsche C.; Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332. bioRxiv 2021","journal-title":"bioRxiv"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3390\/molecules26061678","volume":"26","author":"Baig M.H.","year":"2021","unstructured":"Baig M.H.; Sharma T.; Ahmad I.; Abohashrh M.; Alam M.M.; Dong J.J.; Is PF-00835231 a Pan-SARS-CoV-2 Mpro inhibitor? a comparative study. Molecules 2021,26(6),1678","journal-title":"Molecules"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1002\/hsr2.671","volume":"5","author":"Islam T.","year":"2022","unstructured":"Islam T.; Hasan M.; Rahman M.S.; Islam M.R.; Comparative evaluation of authorized drugs for treating COVID\u201019 patients. Health Sci Rep 2022,5(4),e671","journal-title":"Health Sci Rep"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1021\/acscentsci.2c00369","volume":"8","author":"Halford B.","year":"2022","unstructured":"Halford B.; The Path to Paxlovid. ACS Cent Sci 2022,8(4),405-407","journal-title":"ACS Cent Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1080\/07391102.2020.1767691","volume":"39","author":"Hendaus M.A.","year":"2021","unstructured":"Hendaus M.A.; Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. J Biomol Struct Dyn 2021,39(10),3787-3792","journal-title":"J Biomol Struct Dyn"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"101647","DOI":"10.1016\/j.tmaid.2020.101647","volume":"35","author":"Cao Y.","year":"2020","unstructured":"Cao Y.; Deng Q.; Dai S.; Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis 2020,35,101647","journal-title":"Travel Med Infect Dis"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","volume":"102","author":"Joshi S.","year":"2021","unstructured":"Joshi S.; Parkar J.; Ansari A.; Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021,102,501-508","journal-title":"Int J Infect Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Furuta Y.","year":"2013","unstructured":"Furuta Y.; Gowen B.B.; Takahashi K.; Shiraki K.; Smee D.F.; Barnard D.L.; Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013,100(2),446-454","journal-title":"Antiviral Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"129","DOI":"10.12688\/f1000research.22457.2","volume":"9","author":"Chen Y.W.","year":"2020","unstructured":"Chen Y.W.; Yiu C.P.B.; Wong K.Y.; Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000 Res 2020,9,129","journal-title":"F1000 Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pharma.2017.07.005","volume":"76","author":"Baker M.M.","year":"2018","unstructured":"Baker M.M.; El-Kafrawy D.S.; Mahrous M.S.; Belal T.S.; Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir. Ann Pharm Fr 2018,76(1),16-31","journal-title":"Ann Pharm Fr"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/jac\/dkab072","volume":"76","author":"Sacramento C.Q.","year":"2021","unstructured":"Sacramento C.Q.; Fintelman-Rodrigues N.; Temerozo J.R.; In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother 2021,76(7),1874-1885","journal-title":"J Antimicrob Chemother"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.onehlt.2020.100128","volume":"9","author":"Amirian E.S.","year":"2020","unstructured":"Amirian E.S.; Levy J.K.; Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health 2020,9,100128","journal-title":"One Health"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/v13071369","volume":"13","author":"Rasmussen H.B.","year":"2021","unstructured":"Rasmussen H.B.; J&#xFC;rgens G.; Thomsen R.; Cellular uptake and intracellular phosphorylation of GS-441524: Implications for its effectiveness against COVID-19. Viruses 2021,13(7),1369","journal-title":"Viruses"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41467-022-28113-1","volume":"13","author":"Shannon A.","year":"2022","unstructured":"Shannon A.; Fattorini V.; Sama B.; A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat Commun 2022,13(1),621","journal-title":"Nat Commun"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1093\/jac\/dkaa331","volume":"75","author":"Eslami G.","year":"2020","unstructured":"Eslami G.; Mousaviasl S.; Radmanesh E.; The impact of sofosbuvir\/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother 2020,75(11),3366-3372","journal-title":"J Antimicrob Chemother"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1128\/AAC.30.2.201","volume":"30","author":"Gilbert B.E.","year":"1986","unstructured":"Gilbert B.E.; Knight V.; Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986,30(2),201-205","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=129","first-page":"150","author":"Ataei M.","year":"2020","unstructured":"Ataei M.; Hosseinjani H.; Molecular mechanisms of galidesivir as a potential antiviral treatment for COVID-19. J Pharma Care 2020,150-151","journal-title":"J Pharma Care"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"Elfiky A.A.","year":"2020","unstructured":"Elfiky A.A.; Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020,253,117592","journal-title":"Life Sci"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","volume":"50","author":"Painter G.R.","year":"2021","unstructured":"Painter G.R.; Natchus M.G.; Cohen O.; Holman W.; Painter W.P.; Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol 2021,50,17-22","journal-title":"Curr Opin Virol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1021\/acsomega.1c00772","volume":"6","author":"Ahlqvist G.P.","year":"2021","unstructured":"Ahlqvist G.P.; McGeough C.P.; Senanayake C.; Progress toward a large-scale synthesis of molnupiravir (MK-4482, EIDD-2801) from cytidine. ACS Omega 2021,6(15),10396-10402","journal-title":"ACS Omega"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/jac\/dki405","volume":"57","author":"Gish R.G.","year":"2006","unstructured":"Gish R.G.; Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006,57(1),8-13","journal-title":"J Antimicrob Chemother"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1016\/S0960-894X(02)00747-3","volume":"12","author":"Chong Y.","year":"2002","unstructured":"Chong Y.; Chu C.K.; Understanding the unique mechanism of l-FMAU (Clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg Med Chem Lett 2002,12(23),3459-3462","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41392-022-00963-7","volume":"7","author":"Zhang R.","year":"2022","unstructured":"Zhang R.; Zhang Y.; Zheng W.; Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct Target Ther 2022,7(1),123","journal-title":"Signal Transduct Target Ther"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","volume":"43","author":"Kai H.","year":"2020","unstructured":"Kai H.; Kai M.; Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-Lessons from available evidence and insights into COVID-19. Hypertens Res 2020,43(7),648-654","journal-title":"Hypertens Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"o463","DOI":"10.1107\/S1600536801006948","volume":"57","author":"Nagel N.","year":"2001","unstructured":"Nagel N.; Schweitzer H.; Urbach H.; Heyse W.; M&#xFC;ller B.; Berchtold H.; Ramipril. Acta Crystallogr Sect E Struct Rep Online 2001,57(5),o463-o465","journal-title":"Acta Crystallogr Sect E Struct Rep Online"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1089\/omi.2020.0071","volume":"24","author":"Sachdeva C.","year":"2020","unstructured":"Sachdeva C.; Wadhwa A.; Kumari A.; Hussain F.; Jha P.; Kaushik N.K.; In silico potential of approved antimalarial drugs for repurposing against COVID-19. OMICS 2020,24(10),568-580","journal-title":"OMICS"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1038\/ncomms5029","volume":"5","author":"Birth D.","year":"2014","unstructured":"Birth D.; Kao W.C.; Hunte C.; Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat Commun 2014,5(1),4029","journal-title":"Nat Commun"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"BSR20201256","DOI":"10.1042\/BSR20201256","volume":"40","author":"Shamsi A.","year":"2020","unstructured":"Shamsi A.; Mohammad T.; Anwar S.; Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: Possible implication in COVID-19 therapy. Biosci Rep 2020,40(6),BSR20201256","journal-title":"Biosci Rep"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"39808","DOI":"10.1039\/D0RA08228G","volume":"10","author":"Chatterjee B.","year":"2020","unstructured":"Chatterjee B.; Thakur S.S.; ACE2 as a potential therapeutic target for pandemic COVID-19. RSC Advances 2020,10(65),39808-39813","journal-title":"RSC Advances"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1517\/17460441.1.6.609","volume":"1","author":"Bhardwaj G.","year":"2006","unstructured":"Bhardwaj G.; How the antihypertensive losartan was discovered. Expert Opin Drug Discov 2006,1(6),609-618","journal-title":"Expert Opin Drug Discov"},{"key":"ref=143","first-page":"01","volume":"6","author":"Abbas AM","year":"2020","unstructured":"Abbas AM; Ebrahim IM; Ramadan AG; Ali AR; Isotretinoin: a potential treatment for COVID-19. World J Pharm Res 2020,6(8),01-3","journal-title":"World J Pharm Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2147\/CCID.S259048","volume":"13","author":"Forouzani-Haghighi B.","year":"2020","unstructured":"Forouzani-Haghighi B.; Karimzadeh I.; Isotretinoin and the kidney: opportunities and threats. Clin Cosmet Investig Dermatol 2020,13,485-494","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"588724","DOI":"10.3389\/fimmu.2020.588724","volume":"11","author":"Barbieri A.","year":"2020","unstructured":"Barbieri A.; Robinson N.; Palma G.; Maurea N.; Desiderio V.; Botti G.; Can beta-2-adrenergic pathway be a new target to combat SARS-CoV-2 hyperinflammatory syndrome?\u2014lessons learned from cancer. Front Immunol 2020,11,588724","journal-title":"Front Immunol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/qua.560200109","volume":"20","author":"Phadke R.S.","year":"1981","unstructured":"Phadke R.S.; Kumar N.V.; Hosur R.V.; Saran A.; Govil G.; Structure and function of propranolol: A? -adrenergic blocking drug. Int J Quantum Chem 1981,20(1),85-92","journal-title":"Int J Quantum Chem"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"8612","DOI":"10.3390\/ijms21228612","volume":"21","author":"Bellis A.","year":"2020","unstructured":"Bellis A.; Mauro C.; Barbato E.; Trimarco B.; Morisco C.; The rationale for angiotensin receptor neprilysin inhibitors in a multi-targeted therapeutic approach to COVID-19. Int J Mol Sci 2020,21(22),8612","journal-title":"Int J Mol Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s12272-012-0713-7","volume":"35","author":"Tran T.T.D.","year":"2012","unstructured":"Tran T.T.D.; Tran P.H.L.; Park J.B.; Lee B.J.; Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan. Arch Pharm Res 2012,35(7),1223-1230","journal-title":"Arch Pharm Res"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"172782","DOI":"10.1016\/j.ejphar.2019.172782","volume":"865","author":"Glossmann H.H.","year":"2019","unstructured":"Glossmann H.H.; Lutz O.M.D.; Pharmacology of metformin-An update. Eur J Pharmacol 2019,865,172782","journal-title":"Eur J Pharmacol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"Wang X.","year":"2020","unstructured":"Wang X.; Cao R.; Zhang H.; The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 2020,6(1),28","journal-title":"Cell Discov"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.1016\/j.bmc.2014.09.013","volume":"22","author":"Di Mola A.","year":"2014","unstructured":"Di Mola A.; Peduto A.; La Gatta A.; Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication. Bioorg Med Chem 2014,22(21),6014-6025","journal-title":"Bioorg Med Chem"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"e9003","DOI":"10.1002\/rcm.9003","volume":"35","author":"Sang H.","year":"2021","unstructured":"Sang H.; Wang Y.; Zhong Y.; Quantitative determination of proxalutamide in rat plasma and tissues using liquid chromatography\/tandem mass spectrometry. Rapid Commun Mass Spectrom 2021,35(3),e9003","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/mutage\/14.5.463","volume":"14","author":"Martelli A.","year":"1999","unstructured":"Martelli A.; Mattioli F.; Carrozzino R.; Genotoxicity testing of potassium canrenoate in cultured rat and human cells. Mutagenesis 1999,14(5),463-472","journal-title":"Mutagenesis"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jpids\/piaa117","volume":"9","author":"Lang P.","year":"2020","unstructured":"Lang P.; Eichholz T.; Bakchoul T.; Defibrotide for the treatment of pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection in 2 pediatric patients. J Pediatric Infect Dis Soc 2020,9(5),622-625","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.3390\/md12074086","volume":"12","author":"Yang Y.","year":"2014","unstructured":"Yang Y.; Ma J.; Xiu J.; Deferoxamine compensates for decreases in B cell counts and reduces mortality in enterovirus 71-infected mice. Mar Drugs 2014,12(7),4086-4095","journal-title":"Mar Drugs"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13063-021-05137-4","volume":"22","author":"Wel&#xE9;n K.","year":"2021","unstructured":"Wel&#xE9;n K.; &#xD6;verby A.K.; Ahlm C.; COVIDENZA - A prospective, multicenter, randomized phase II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials 2021,22(1),209","journal-title":"Trials"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41391-019-0195-5","volume":"23","author":"Ryan C.","year":"2020","unstructured":"Ryan C.; Wefel J.S.; Morgans A.K.; A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis 2020,23(2),207-219","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Schroeder S.; Kleine-Weber H.; M&#xFC;ller M.A.; Drosten C.; P&#xF6;hlmann S.; Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 2020,64(6),e00754-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"26895","DOI":"10.1039\/D0RA05821A","volume":"10","author":"Abuo-Rahma G.E.D.A.","year":"2020","unstructured":"Abuo-Rahma G.E.D.A.; Mohamed M.F.A.; Ibrahim T.S.; Shoman M.E.; Samir E.; Abd El-Baky R.M.; Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. RSC Advances 2020,10(45),26895-26916","journal-title":"RSC Advances"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/pharmaceutics13060815","volume":"13","author":"Costa B.","year":"2021","unstructured":"Costa B.; Vale N.; A review of repurposed cancer drugs in clinical trials for potential treatment of COVID-19. Pharmaceutics 2021,13(6),815","journal-title":"Pharmaceutics"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10822-016-9992-2","volume":"30","author":"Liu H.","year":"2016","unstructured":"Liu H.; Han R.; Li J.; Liu H.; Zheng L.; Molecular mechanism of] R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation. J Comput Aided Mol Des 2016,30(12),1189-1200","journal-title":"J Comput Aided Mol Des"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00228-020-02971-4","volume":"77","author":"Fu Q.","year":"2021","unstructured":"Fu Q.; Zheng X.; Zhou Y.; Tang L.; Chen Z.; Ni S.; Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19. Eur J Clin Pharmacol 2021,77(2),261-263","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.talanta.2007.05.010","volume":"73","author":"Turch&#xE1;n M.","year":"2007","unstructured":"Turch&#xE1;n M.; Jaraulloa P.; Bollo S.; Nu&#xF1;ezvergara L.; Squella J.; Alvarezlueje A.; Voltammetric behaviour of bromhexine and its determination in pharmaceuticals. Talanta 2007,73(5),913-919","journal-title":"Talanta"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jsps.2022.01.005","volume":"30","author":"Sharma T.","year":"2022","unstructured":"Sharma T.; Baig M.H.; Khan M.I.; Alotaibi S.S.; Alorabi M.; Dong J.J.; Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19. Saudi Pharm J 2022,30(3),217-224","journal-title":"Saudi Pharm J"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1124\/jpet.108.148155","volume":"329","author":"Coote K.","year":"2009","unstructured":"Coote K.; Atherton-Watson H.C.; Sugar R.; Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther 2009,329(2),764-774","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fmed.2020.00453","volume":"7","author":"Cadegiani F.A.","year":"2020","unstructured":"Cadegiani F.A.; Wambier C.; Goren A.; Spironolactone. an anti-androgenic and anti-hypertensive drug with strong potential to prevent COVID-19 induced acute respiratory distress syndrome (ARDS). Fron Med 2020,7,453","journal-title":"Fron Med"},{"key":"ref=167","first-page":"756","volume":"11","author":"Mousa M.","year":"2021","unstructured":"Mousa M.; Effect of disintegrants on spironolactone tablet stability. Int J Drug Deliv 2021,11,756-761","journal-title":"Int J Drug Deliv"},{"key":"ref=168","author":"Huang A","year":"2020","unstructured":"Huang A; Tang X; Wu H; Virtual screening and molecular dynamics on blockage of key drug targets as treatment for COVID-19 caused by SARS-CoV-2. medicine  2020","journal-title":"medicine"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0300-483X(98)00109-7","volume":"130","author":"G&#xF3;mez M.","year":"1998","unstructured":"G&#xF3;mez M.; Esparza J.L.; Domingo J.L.; Singh P.K.; Jones M.M.; Comparative aluminium mobilizing actions of deferoxamine and four 3-hydroxypyrid-4-ones in aluminium-loaded rats. Toxicology 1998,130(2-3),175-181","journal-title":"Toxicology"},{"key":"ref=170","author":"Dayer MR","year":"2020","unstructured":"Dayer MR; Old drugs for newly emerging viral disease, COVID-19: Bioinformatic Prospective 2020","journal-title":"Bioinformatic Prospective"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1128\/AAC.00743-07","volume":"51","author":"Yamada M.","year":"2007","unstructured":"Yamada M.; Watanabe T.; Miyara T.; Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother 2007,51(11),3902-3907","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","volume":"6","author":"Xu J.","year":"2020","unstructured":"Xu J.; Shi P.Y.; Li H.; Zhou J.; Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 2020,6(5),909-915","journal-title":"ACS Infect Dis"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"17530","DOI":"10.1074\/jbc.M112.359638","volume":"287","author":"Fonseca B.D.","year":"2012","unstructured":"Fonseca B.D.; Diering G.H.; Bidinosti M.A.; Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 2012,287(21),17530-17545","journal-title":"J Biol Chem"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1089\/vim.2021.0042","volume":"34","author":"Al-kuraishy H.M.","year":"2021","unstructured":"Al-kuraishy H.M.; Al-Gareeb A.I.; Alkazmi L.; Alexiou A.; Batiha G.E.S.; Levamisole therapy in COVID-19. Viral Immunol 2021,34(10),722-725","journal-title":"Viral Immunol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"e45405","DOI":"10.1371\/journal.pone.0045405","volume":"7","author":"Hansen A.N.","year":"2012","unstructured":"Hansen A.N.; Bendiksen C.D.; Sylvest L.; Synthesis and antiangiogenic activity of N-alkylated levamisole derivatives. PLoS One 2012,7(9),e45405","journal-title":"PLoS One"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/molecules27030658","volume":"27","author":"Men&#xE9;ndez J.C.","year":"2022","unstructured":"Men&#xE9;ndez J.C.; Approaches to the potential therapy of COVID-19: A general overview from the medicinal chemistry perspective. Molecules 2022,27(3),658","journal-title":"Molecules"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"13349","DOI":"10.1039\/D1CC03678E","volume":"57","author":"Lengacher R.","year":"2021","unstructured":"Lengacher R.; Wang Y.; Braband H.; Blacque O.; Gasser G.; Alberto R.; Organometallic small molecule kinase inhibitors-Direct incorporation of Re and 99mTc into Opaganib&#xAE;. Chem Commun (Camb) 2021,57(98),13349-13352","journal-title":"Chem Commun (Camb)"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"198246","DOI":"10.1016\/j.virusres.2020.198246","volume":"292","author":"Luban J.","year":"2021","unstructured":"Luban J.; Sattler R.A.; M&#xFC;hlberger E.; The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res 2021,292,198246","journal-title":"Virus Res"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-18-0863","volume":"18","author":"Cao L.","year":"2019","unstructured":"Cao L.; Weetall M.; Trotta C.; Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties. Mol Cancer Ther 2019,18(1),3-16","journal-title":"Mol Cancer Ther"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-020-0158-2","volume":"5","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Jiang W.; He Q.; A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther 2020,5(1),57","journal-title":"Signal Transduct Target Ther"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00216-011-4744-6","volume":"400","author":"Panusa A.","year":"2011","unstructured":"Panusa A.; Regazzoni L.; Aldini G.; Urinary profile of methylprednisolone acetate metabolites in patients following intra-articular and intramuscular administration. Anal Bioanal Chem 2011,400(1),255-267","journal-title":"Anal Bioanal Chem"},{"key":"ref=182","first-page":"5","volume":"1","author":"Alizadehmohajer N.","year":"2020","unstructured":"Alizadehmohajer N.; Sadeghi B.; Najafgholian S.; Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking. Life Sci 2020,1,5-5","journal-title":"Life Sci"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.medidd.2020.100035","volume":"6","author":"Mao L.","year":"2020","unstructured":"Mao L.; Tang W.; Zhang X.; Discovery of a novel, selective and irreversible inhibitor (abivertinib) of mutated EGFR and T790M-induced resistance for the treatment of NSCLC. Med Drug Discov 2020,6,100035","journal-title":"Med Drug Discov"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"2000224","DOI":"10.1002\/adtp.202000224","volume":"4","author":"Yang C.","year":"2021","unstructured":"Yang C.; Pan X.; Huang Y.; Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID\u201019 by Blocking SARS\u2010CoV\u20102 Spike Protein\u2010Mediated Membrane Fusion. Adv Ther 2021,4(5),2000224","journal-title":"Adv Ther"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0039-128X(96)00242-5","volume":"62","author":"Anstead G.M.","year":"1997","unstructured":"Anstead G.M.; Carlson K.E.; Katzenellenbogen J.A.; The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997,62(3),268-303","journal-title":"Steroids"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"861","DOI":"10.22207\/JPAM.14.SPL1.23","volume":"14","author":"Dhameliya H.","year":"2020","unstructured":"Dhameliya H.; Thakkar V.; Trivedi G.; Mesara S.; Subramanian R.; Pentoxifylline: an immunomodulatory drug for the treatment of COVID-19. J Pure Appl Microbiol 2020,14(Suppl. 1),861-867","journal-title":"J Pure Appl Microbiol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4103\/2229-5178.142528","volume":"5","author":"Hassan I.","year":"2014","unstructured":"Hassan I.; Dorjay K.; Anwar P.; Pentoxifylline and its applications in dermatology. Indian Dermatol Online J 2014,5(4),510-516","journal-title":"Indian Dermatol Online J"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.2337\/dc20-2018","volume":"44","author":"Grenet G.","year":"2021","unstructured":"Grenet G.; Mekhaldi S.; Mainbourg S.; DPP-4 inhibitors and respiratory infection: a systematic review and meta-analysis of the cardiovascular outcomes trials. Diabetes Care 2021,44(3),e36-e37","journal-title":"Diabetes Care"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1758-5996-5-25","volume":"5","author":"Guedes E.P.","year":"2013","unstructured":"Guedes E.P.; Hohl A.; de Melo T.G.; Lauand F.; Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr 2013,5(1),25","journal-title":"Diabetol Metab Syndr"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1529\/biophysj.106.089581","volume":"91","author":"Meier M.","year":"2006","unstructured":"Meier M.; Blatter X.L.; Seelig A.; Seelig J.; Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity. Biophys J 2006,91(8),2943-2955","journal-title":"Biophys J"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1021\/acschemneuro.8b00258","volume":"10","author":"Boyd-Kimball D.","year":"2019","unstructured":"Boyd-Kimball D.; Gonczy K.; Lewis B.; Mason T.; Siliko N.; Wolfe J.; Classics in chemical neuroscience: chlorpromazine. ACS Chem Neurosci 2019,10(1),79-88","journal-title":"ACS Chem Neurosci"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"112739","DOI":"10.1016\/j.ejmech.2020.112739","volume":"207","author":"Firth A.","year":"2020","unstructured":"Firth A.; Prathapan P.; Azithromycin: the first broad-spectrum Therapeutic. Eur J Med Chem 2020,207,112739","journal-title":"Eur J Med Chem"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"112222","DOI":"10.1016\/j.ejmech.2020.112222","volume":"193","author":"Fan B.Z.","year":"2020","unstructured":"Fan B.Z.; Hiasa H.; Lv W.; Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone\/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides. Eur J Med Chem 2020,193,112222","journal-title":"Eur J Med Chem"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"e00864","DOI":"10.1016\/j.idcr.2020.e00864","volume":"21","author":"Malek A.E.","year":"2020","unstructured":"Malek A.E.; Granwehr B.P.; Kontoyiannis D.P.; Doxycycline as a potential partner of COVID-19 therapies. IDCases 2020,21,e00864","journal-title":"IDCases"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0065-2164(08)70405-2","volume":"13","author":"Blackwood R.K.","year":"1970","unstructured":"Blackwood R.K.; English A.R.; Structure-activity relationships in the tetracycline series. In: Advances in Applied Microbiology. Adv Appl Microbiol 1970,13,237-266","journal-title":"Adv Appl Microbiol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.drudis.2020.06.018","volume":"25","author":"Duan Y.","year":"2020","unstructured":"Duan Y.; Yao Y.; Kumar S.A.; Zhu H.L.; Chang J.; Current and future therapeutical approaches for COVID-19. Drug Discov Today 2020,25(8),1545-1552","journal-title":"Drug Discov Today"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"111566","DOI":"10.1016\/j.ejmech.2019.111566","volume":"181","author":"Huang Y.M.","year":"2019","unstructured":"Huang Y.M.; Alharbi N.S.; Sun B.; Shantharam C.S.; Rakesh K.P.; Qin H.L.; Synthetic routes and structure-activity relationships (SAR) of anti-HIV agents: A key review. Eur J Med Chem 2019,181,111566","journal-title":"Eur J Med Chem"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s43440-020-00195-y","volume":"73","author":"Kaur H.","year":"2021","unstructured":"Kaur H.; Shekhar N.; Sharma S.; Sarma P.; Prakash A.; Medhi B.; Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep 2021,73(3),736-749","journal-title":"Pharmacol Rep"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0169-4758(85)90100-0","volume":"1","author":"Campbell W.C.","year":"1985","unstructured":"Campbell W.C.; Ivermectin: An update. Parasitol Today 1985,1(1),10-16","journal-title":"Parasitol Today"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","volume":"23","author":"Herman S.E.M.","year":"2017","unstructured":"Herman S.E.M.; Montraveta A.; Niemann C.U.; The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res 2017,23(11),2831-2841","journal-title":"Clin Cancer Res"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"113724","DOI":"10.1016\/j.ejmech.2021.113724","volume":"225","author":"Zhang D.","year":"2021","unstructured":"Zhang D.; Xu G.; Zhao J.; Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton\u2019s tyrosine kinase. Eur J Med Chem 2021,225,113724","journal-title":"Eur J Med Chem"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"7071","DOI":"10.3390\/ijms22137071","volume":"22","author":"Kaliamurthi S.","year":"2021","unstructured":"Kaliamurthi S.; Selvaraj G.; Selvaraj C.; Singh S.K.; Wei D.Q.; Peslherbe G.H.; Structure-based virtual screening reveals Ibrutinib and Zanubrutinib as potential repurposed drugs against COVID-19. Int J Mol Sci 2021,22(13),7071","journal-title":"Int J Mol Sci"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1016\/j.bmcl.2016.05.014","volume":"26","author":"Zou Y.","year":"2016","unstructured":"Zou Y.; Xiao J.; Tu Z.; Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton\u2019s tyrosine kinase inhibitors. Bioorg Med Chem Lett 2016,26(13),3052-3059","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00726-020-02887-4","volume":"52","author":"Yin Z.","year":"2020","unstructured":"Yin Z.; Hu W.; Zhang W.; Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. Amino Acids 2020,52(9),1227-1261","journal-title":"Amino Acids"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.drudis.2021.11.002","volume":"27","author":"Basile M.S.","year":"2022","unstructured":"Basile M.S.; Cavalli E.; McCubrey J.; The PI3K\/Akt\/mTOR pathway: A potential pharmacological target in COVID-19. Drug Discov Today 2022,27(3),848-856","journal-title":"Drug Discov Today"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/ph12020069","volume":"12","author":"Rodrigues D.A.","year":"2019","unstructured":"Rodrigues D.A.; Sagrillo F.S.; Fraga C.A.M.; Duvelisib: a 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-kinases. Pharmaceuticals 2019,12(2),69","journal-title":"Pharmaceuticals"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"106749","DOI":"10.1016\/j.intimp.2020.106749","volume":"86","author":"Zhang X.","year":"2020","unstructured":"Zhang X.; Zhang Y.; Qiao W.; Zhang J.; Qi Z.; Baricitinib, a drug with potential effect to prevent SARS-CoV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol 2020,86,106749","journal-title":"Int Immunopharmacol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/ph14070680","volume":"14","author":"Saber-Ayad M.","year":"2021","unstructured":"Saber-Ayad M.; Hammoudeh S.; Abu-Gharbieh E.; Current status of baricitinib as a repurposed therapy for COVID-19. Pharmaceuticals 2021,14(7),680","journal-title":"Pharmaceuticals"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"108517","DOI":"10.1016\/j.clim.2020.108517","volume":"218","author":"Yeleswaram S.","year":"2020","unstructured":"Yeleswaram S.; Smith P.; Burn T.; Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Clin Immunol 2020,218,108517","journal-title":"Clin Immunol"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1111\/febs.15784","volume":"288","author":"Merzon E.","year":"2021","unstructured":"Merzon E.; Green I.; Vinker S.; The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID\u201019 infection. FEBS J 2021,288(17),5179-5189","journal-title":"FEBS J"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1039\/jr9640006036","author":"Wheatley P.J.","year":"1964","unstructured":"Wheatley P.J.; 1163. The crystal and molecular structure of aspirin. J Chem Soc 1964,6036-6048","journal-title":"J Chem Soc"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"B&#xFC;ller H.R.","year":"2013","unstructured":"B&#xFC;ller H.R.; D&#xE9;cousus H.; Grosso M.A.; Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013,369(15),1406-1415","journal-title":"N Engl J Med"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S0885715621000117","volume":"36","author":"Kaduk J.A.","year":"2021","unstructured":"Kaduk J.A.; Gindhart A.M.; Blanton T.N.; Crystal structure of edoxaban tosylate monohydrate Form I, (C24H31ClN7O4S)(C7H7O3S)(H2O). Powder Diffr 2021,36(2),107-113","journal-title":"Powder Diffr"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12967-020-02439-0","volume":"18","author":"Aftab S.O.","year":"2020","unstructured":"Aftab S.O.; Ghouri M.Z.; Masood M.U.; Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med 2020,18(1),275","journal-title":"J Transl Med"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"e04502","DOI":"10.1016\/j.heliyon.2020.e04502","volume":"6","author":"Ahmad J.","year":"2020","unstructured":"Ahmad J.; Ikram S.; Ahmad F.; Rehman I.U.; Mushtaq M.; SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) \u2013 A drug repurposing study. Heliyon 2020,6(7),e04502","journal-title":"Heliyon"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13321-017-0202-6","volume":"9","author":"Van Den Driessche G.","year":"2017","unstructured":"Van Den Driessche G.; Fourches D.; Adverse drug reactions triggered by the common HLA-B*57:01 variant: A molecular docking study. J Cheminform 2017,9(1),13","journal-title":"J Cheminform"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"Madhavi Sastry G.","year":"2013","unstructured":"Madhavi Sastry G.; Adzhigirey M.; Day T.; Annabhimoju R.; Sherman W.; Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 2013,27(3),221-234","journal-title":"J Comput Aided Mol Des"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13065-018-0475-5","volume":"12","author":"Kumar S.","year":"2018","unstructured":"Kumar S.; Singh J.; Narasimhan B.; Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. Chem Cent J 2018,12(1),106","journal-title":"Chem Cent J"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"117652","DOI":"10.1016\/j.lfs.2020.117652","volume":"252","author":"Shah B.","year":"2020","unstructured":"Shah B.; Modi P.; Sagar S.R.; In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci 2020,252,117652","journal-title":"Life Sci"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2022.2051745","author":"Singh Y.","year":"2022","unstructured":"Singh Y.; Sanjay K.S.; Pradeep Kumar, Singh S, Thareja S. Molecular dynamics and 3D-QSAR studies on indazole derivatives as HIF-1&#x3B1; inhibitors. J Biomol Struct Dyn 2022,1-18","journal-title":"J Biomol Struct Dyn"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1039\/D0FO01511C","volume":"11","author":"Brogi S.","year":"2020","unstructured":"Brogi S.; Sirous H.; Calderone V.; Chemi G.; Amyloid &#x3B2; fibril disruption by oleuropein aglycone: long-time molecular dynamics simulation to gain insight into the mechanism of action of this polyphenol from extra virgin olive oil. Food Funct 2020,11(9),8122-8132","journal-title":"Food Funct"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221107123841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210693\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221107123841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:20:14Z","timestamp":1691727614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210693\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":221,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612829666221107123841","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}